AI Analysis

How does WALD make money? Does WALD have pricing power? What's the Earnings Whisper? Will WALD profit more as the business scales? What is WALD's management track record? Is WALD's current price justified?

Waldencast plc

$1.31 -$0.40 (-23.39%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$1.33

Day Range

$1.3$1.33

Year Range

$0.72$3.22

Market Cap

154.89M

AVG Volume

1.34M

Trailing/Forward PE

-0.65/-

PEG ratio

0.09

Dividend Yield

Next Earnings Date

2026-09-14

Primary Exchange

NASDAQ

Employee Count

WALD Employee Count by quarter
Period	Employee Count
2025	248
2024	174
2023	165
2022	187
2022	187

Free Cash Flow Yield

WALD Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-17.93%
Sep 26	-17.15%
Aug 26	-17.53%
Aug 26	-18.07%
Aug 26	-17.4%
Aug 26	-16.9%
Jul 26	-13.58%
Jul 26	-13.9%
Jul 26	-13.58%
Jul 26	-13.58%
Jul 26	-13.98%
Jun 26	-16.09%
Jun 26	-14.15%
Jun 26	-12.63%
Jun 26	-13.66%
May 26	-19.1%
May 26	-18.07%
May 26	-15.98%
May 26	-13.05%
May 26	-24.44%
Apr 26	-27.59%
Apr 26	-22.59%
Apr 26	-22.59%
Apr 26	-26.14%
Mar 26	-23.97%
Mar 26	-19.74%
Mar 26	-14.87%
Mar 26	-22.36%
Feb 26	-20.77%
Feb 26	-19.5%
Feb 26	-19.5%
Feb 26	-19.5%
Jan 26	-19.39%
Jan 26	-20.17%
Jan 26	-21.4%
Jan 26	-23.72%
Jan 26	-20.53%
Dec 25	-17.64%
Dec 25	-18.09%
Dec 25	-18.97%
Dec 25	-15.07%
Nov 25	-13.93%
Nov 25	-11.4%
Nov 25	-18.57%
Nov 25	-19.29%
Oct 25	-19.39%
Oct 25	-18.28%
Oct 25	-18.57%
Oct 25	-18.87%
Oct 25	-18.77%
Sep 25	-17.38%
Sep 25	-16.88%
Sep 25	-19.39%
Sep 25	-19.72%
Aug 25	-22.5%
Aug 25	-35.18%
Aug 25	-35.18%
Aug 25	-37.11%
Aug 25	-35.8%
Jul 25	-26.69%
Jul 25	-26.46%
Jul 25	-23.96%
Jul 25	-21.58%
Jun 25	-23.41%
Jun 25	-27.05%
Jun 25	-27.67%
Jun 25	-24.84%
May 25	-22.63%
May 25	-25.68%
May 25	-28.85%
May 25	-21.58%
May 25	-21.89%
Apr 25	-22.63%
Apr 25	-23.23%
Apr 25	-24.94%
Apr 25	-23.96%
Mar 25	-20.36%
Mar 25	-19.57%
Mar 25	-24.76%
Mar 25	-24.16%
Feb 25	-24.38%
Feb 25	-25.15%
Feb 25	-25.89%
Feb 25	-22.45%
Jan 25	-22.97%
Jan 25	-23.59%
Jan 25	-26.41%
Jan 25	-27.13%
Jan 25	-23.17%
Dec 24	-20.07%
Dec 24	-21.78%
Dec 24	-20.43%
Dec 24	-25.23%
Nov 24	-23.52%
Nov 24	-23.94%
Nov 24	-24.68%
Nov 24	-22.45%
Nov 24	-24.31%
Oct 24	-22.77%
Oct 24	-23.24%

Price to Sales

WALD Price to Sales by quarter
Period	Price to Sales
Sep 26	0.28
Sep 26	0.3
Aug 26	0.29
Aug 26	0.28
Aug 26	0.29
Aug 26	0.3
Jul 26	0.37
Jul 26	0.37
Jul 26	0.37
Jul 26	0.37
Jul 26	0.36
Jun 26	0.32
Jun 26	0.36
Jun 26	0.4
Jun 26	0.37
May 26	0.27
May 26	0.28
May 26	0.32
May 26	0.39
May 26	0.21
Apr 26	0.18
Apr 26	0.23
Apr 26	0.23
Apr 26	0.19
Mar 26	0.21
Mar 26	0.26
Mar 26	0.34
Mar 26	0.34
Feb 26	0.37
Feb 26	0.39
Feb 26	0.39
Feb 26	0.39
Jan 26	0.4
Jan 26	0.38
Jan 26	0.36
Jan 26	0.32
Jan 26	0.37
Dec 25	0.43
Dec 25	0.42
Dec 25	0.4
Dec 25	0.51
Nov 25	0.55
Nov 25	0.67
Nov 25	0.41
Nov 25	0.4
Oct 25	0.4
Oct 25	0.42
Oct 25	0.41
Oct 25	0.41
Oct 25	0.41
Sep 25	0.44
Sep 25	0.45
Sep 25	0.4
Sep 25	0.39
Aug 25	0.34
Aug 25	0.42
Aug 25	0.42
Aug 25	0.39
Aug 25	0.41
Jul 25	0.55
Jul 25	0.55
Jul 25	0.61
Jul 25	0.68
Jun 25	0.63
Jun 25	0.54
Jun 25	0.53
Jun 25	0.59
May 25	0.65
May 25	0.57
May 25	0.51
May 25	0.68
May 25	0.67
Apr 25	0.65
Apr 25	0.63
Apr 25	0.59
Apr 25	0.61
Mar 25	0.72
Mar 25	0.75
Mar 25	0.81
Mar 25	0.83
Feb 25	0.82
Feb 25	0.79
Feb 25	0.77
Feb 25	0.89
Jan 25	0.87
Jan 25	0.85
Jan 25	0.76
Jan 25	0.74
Jan 25	0.86
Dec 24	1
Dec 24	0.92
Dec 24	0.98
Dec 24	0.79
Nov 24	0.85
Nov 24	0.83
Nov 24	0.81
Nov 24	0.89
Nov 24	0.82
Oct 24	0.88
Oct 24	0.86

EV/EBITDA

WALD EV/EBITDA by quarter
Period	EV/EBITDA
Aug 22	17.68
Aug 22	17.38
Aug 22	14.82
Aug 22	15.62
Jul 22	16.69
Jul 22	17.08
Jul 22	18.72
Jul 22	18.68
Jul 22	18.53
Jun 22	18.49
Jun 22	18.46
Jun 22	18.51
Jun 22	18.5
May 22	18.5
May 22	18.56
May 22	18.6
May 22	18.66
Apr 22	18.59
Apr 22	18.59
Apr 22	18.62
Apr 22	18.59
Apr 22	18.58

Price to Book

WALD Price to Book by quarter
Period	Price to Book
Sep 26	0.31
Sep 26	0.32
Aug 26	0.32
Aug 26	0.31
Aug 26	0.32
Aug 26	0.33
Jul 26	0.41
Jul 26	0.4
Jul 26	0.41
Jul 26	0.41
Jul 26	0.4
Jun 26	0.35
Jun 26	0.39
Jun 26	0.44
Jun 26	0.41
May 26	0.29
May 26	0.31
May 26	0.35
May 26	0.43
May 26	0.23
Apr 26	0.2
Apr 26	0.25
Apr 26	0.25
Apr 26	0.21
Mar 26	0.23
Mar 26	0.28
Mar 26	0.37
Mar 26	0.32
Feb 26	0.35
Feb 26	0.37
Feb 26	0.37
Feb 26	0.37
Jan 26	0.37
Jan 26	0.36
Jan 26	0.34
Jan 26	0.3
Jan 26	0.35
Dec 25	0.41
Dec 25	0.4
Dec 25	0.38
Dec 25	0.48
Nov 25	0.52
Nov 25	0.63
Nov 25	0.39
Nov 25	0.37
Oct 25	0.37
Oct 25	0.39
Oct 25	0.39
Oct 25	0.38
Oct 25	0.38
Sep 25	0.41
Sep 25	0.43
Sep 25	0.37
Sep 25	0.36
Aug 25	0.32
Aug 25	0.27
Aug 25	0.27
Aug 25	0.26
Aug 25	0.26
Jul 25	0.35
Jul 25	0.36
Jul 25	0.4
Jul 25	0.44
Jun 25	0.4
Jun 25	0.35
Jun 25	0.34
Jun 25	0.38
May 25	0.42
May 25	0.37
May 25	0.33
May 25	0.44
May 25	0.43
Apr 25	0.42
Apr 25	0.41
Apr 25	0.38
Apr 25	0.4
Mar 25	0.47
Mar 25	0.48
Mar 25	0.47
Mar 25	0.48
Feb 25	0.47
Feb 25	0.46
Feb 25	0.45
Feb 25	0.51
Jan 25	0.5
Jan 25	0.49
Jan 25	0.44
Jan 25	0.43
Jan 25	0.5
Dec 24	0.58
Dec 24	0.53
Dec 24	0.57
Dec 24	0.46
Nov 24	0.49
Nov 24	0.48
Nov 24	0.47
Nov 24	0.51
Nov 24	0.47
Oct 24	0.51
Oct 24	0.5

No video analysis for this stock yet. Request one from our team.

News: WALD

globenewswire.com · 30 Jul 2026

Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.

globenewswire.com · 15 Jun 2026

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (“HA”) gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand. This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive leader at the intersection of advanced skincare and medical aesthetics.

AI Analysis

Waldencast plc

Video analysis: WALD

News: WALD

Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

Similar companies